A 30-year experienced pharmacist has expressed concerns over the potential risks of weight loss drugs due to emerging alarming side effects. Originally intended for diabetes control, these drugs are now commonly used for weight loss, with approximately 1.5 million individuals in the UK already utilizing them.
Deborah Grayson, the proprietor of Digestion with Confidence, has highlighted the worrisome long-term consequences that may arise from even short-term usage of these injections. She has observed an increase in patients suffering from severe and enduring gut issues caused by weight-loss injections designed to aid them. One prevalent condition she has noted is gastroparesis, characterized by delayed gastric emptying, leading to symptoms like feeling full quickly, nausea, vomiting, bloating, stomach pain, and heartburn.
Although delayed gastric emptying is considered uncommon as a side effect, the potential for permanent gastroparesis is not listed on the manufacturer’s data sheet for weight loss medication. This revelation is troubling as it challenges the belief that these issues resolve upon discontinuation of the injections, leaving many individuals with persistent symptoms affecting their daily lives and nutritional intake.
Gastroparesis, which affects approximately 14 per 100,000 people in the UK, predominantly impacts women and is commonly diagnosed in individuals aged 18 to 39. The NHS advises seeking medical attention if symptoms such as early satiety, nausea, vomiting, stomach pain, heartburn, or bloating persist, as these could indicate gastroparesis.
Ms. Grayson further emphasized the potential risks associated with increased prescriptions of acid-reducing medications due to gut symptoms triggered by weight-loss injections. She cautioned that treating acid-related discomfort with proton pump inhibitors (PPIs) without addressing the underlying issue of delayed stomach emptying can exacerbate symptoms and lead to additional digestive problems.
NHS recommendations for managing gastroparesis include dietary adjustments such as consuming smaller, more frequent meals, reducing indigestible fiber intake, and transitioning to a liquid diet. Ms. Grayson urged patients and healthcare providers to remain vigilant, emphasizing the importance of early symptom recognition to prevent chronic complications and the need for alternative treatments in individuals with gastrointestinal issues.
Furthermore, Ms. Grayson previously raised concerns about the increased incidence of gallbladder removal and pancreatic problems associated with weight loss and diabetes injections. Health officials have initiated a study on these side effects, with reports of fatal cases of pancreatitis linked to GLP-1 medicines. While these drugs can aid in weight loss and managing diabetes, their potential risks, including gastrointestinal side effects, should not be underestimated.